Mechanisms of anabolic therapies for osteoporosis.
Canalis
Ernesto
E
Department of Research, Saint Francis Hospital and Medical Center, Hartford, CT 06105-1299, USA. ecanalis@stfranciscare.org
Giustina
Andrea
A
Bilezikian
John P
JP
D045930:Anabolic Agents / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D019485:Bone Morphogenetic Proteins / Q000502:physiology; D016723:Bone Remodeling / Q000187:drug effects / Q000502:physiology*; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000502:physiology; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy* / Q000503:physiopathology; D010281:Parathyroid Hormone / Q000008:administration & dosage*; D019379:Teriparatide / Q000627:therapeutic use; D051153:Wnt Proteins / Q000037:antagonists & inhibitors / Q000502:physiology
D045930:Anabolic Agents; D050071:Bone Density Conservation Agents; D019485:Bone Morphogenetic Proteins; D010281:Parathyroid Hormone; D051153:Wnt Proteins; D019379:Teriparatide; D007334:Insulin-Like Growth Factor I